Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-113245
Filing Date
2024-10-07
Accepted
2024-10-07 16:35:47
Documents
2
Period of Report
2024-10-03

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1581
2 EX-24.1 inzy-ex24_1.htm EX-24.1 11479
  Complete submission text file 0000950170-24-113245.txt   14555
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Issuer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address
Harris Erik (Reporting) CIK: 0001780113 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39397 | Film No.: 241358230